Results 151 to 160 of about 310,119 (307)

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Correction: Anti-alcoholism drug disulfiram inhibits PANoptosis by blocking mitochondrial permeabilization in macrophages. [PDF]

Front Immunol
Li YP, Niu XJ, Zhang G, Chan OK, Sun N, Hu B, Shi ZJ, Ouyang DY, He XH, Zha QB.   +9 more
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Associations Between Parental Alcohol Use and Parenting Practices: A Systematic Review. [PDF]

Behav Sci (Basel)
Carvalho BO, Stea TH, Coombes L, Haugland SH.   +3 more
europepmc   +1 more source

Morality and Alcoholism [PDF]

, 1951
Furlong, Francis P.
core   +1 more source

Nicotine pouches and clinical outcomes related to smoking cessation: A systematic review of randomized trials

Addiction, EarlyView.
Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati, Spencer Shahen, Emma Lynn Bates, Sarah Visintini, Evyanne Quirouette, Kerri‐Anne Mullen, Hassan Mir   +6 more
wiley   +1 more source

Multivariate genetic analyses of 2.2 million individuals reveal broad and substance-specific pathways of addiction risk. [PDF]

Nat Ment Health
Poore HE, Chatzinakos C, Leger B, Gonzalez J, Mallard TT, Aliev F, Hatoum A, Waldman ID, Sanchez-Roige S, Palmer AA, Harden KP, Dick DM, Barr PB.   +12 more
europepmc   +1 more source

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

Addiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor, Jessica Shields, Asiya Hamid, Eleanor Holman, Hannah Biggs, Sarah Minty, Jamie Pearce, Allison Ford   +7 more
wiley   +1 more source

Ethanol Alters the Neurexin Landscape in Human Neuroblastoma Cells. [PDF]

Alcohol Clin Exp Res (Hoboken)
Lowe CC, Zimmerman KD, Cervera-Juanes R.
europepmc   +1 more source

Alcoholism and Some Moral Issues [PDF]

, 1945
Britt, Robert E.
core   +1 more source